Sanofi must pay up to $109M for Hyalgan kickbacks

Share this article:
Drugmakers Sanofi-Aventis U.S. Inc. and Sanofi-Aventis U.S. LCC will pay up to $109 million in a settlement over an alleged scheme to provide doctors with free units of its knee-injection drug Hyalgan in return for purchase of the treatment.

The action, which was announced Dec. 19, also settled claims that the Paris-based company reported an average sales price (ASP) that omitted the free units of the arthritis-related pain reliever between 2005 and 2009. That led to government overpayment on drug reimbursement rates for Hyalgan and the competing Supartz.

The penalty is the result of information from former Sanofi sales representative Mark Giddarie. The Department of Justice said Giddarie will receive $18.5 million as his share of the settlement proceeds. Multiple states will also share in the federal government's recovery.

Bridgewater, N.J.-based Sanofi US issued a statement saying it “is pleased to have reached a resolution” in the matter.

Share this article:

More in News

Bill addressing admission status receives praise

A bill that would require hospitals to give patients a formal notice of their admission status has received strong support from healthcare associations.

Increased 'bed taxes' on nursing facilities warrant stricter federal oversight, report states

States have been increasingly taxing skilled nursing facilities and other healthcare providers to fund Medicaid in recent years, and federal authorities should look more closely at this trend, according to a government report released Tuesday.

Last chance: Tech Awards deadline arrives

Last chance: Tech Awards deadline arrives

There are hours left for innovative long-term care providers to enter the third annual McKnight's Excellence in Technology Awards. Submissions will be accepted until the stroke of midnight tonight.